An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone

Leuk Lymphoma. 2016 Aug;57(8):1956-60. doi: 10.3109/10428194.2015.1117610. Epub 2016 Jan 4.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / metabolism
  • Antigens, Differentiation, Myelomonocytic / metabolism
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / metabolism*
  • Kaplan-Meier Estimate
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / enzymology
  • Lymphoma, Large B-Cell, Diffuse / metabolism
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Prednisolone / administration & dosage
  • Prognosis
  • Receptors, Cell Surface / metabolism
  • Rituximab / administration & dosage
  • Tetraspanin 30 / metabolism
  • Tumor Microenvironment*
  • Vincristine / administration & dosage

Substances

  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • CD163 antigen
  • Indoleamine-Pyrrole 2,3,-Dioxygenase
  • Receptors, Cell Surface
  • Tetraspanin 30
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone